International Edition
Latest News
Health

UC Berkeley Researchers Find Compound Increases Energy Expenditure 18% in Obese Mice

UC Berkeley researchers identified a compound that increased energy expenditure by 18% in obese mice while preserving lean muscle mass. "Body weight responds to two levers: taking in fewer calories, or spending more energy," said Anders Näär, professor…

UC Berkeley Researchers Find Compound Increases Energy Expenditure 18% in Obese Mice

UC Berkeley researchers identified a compound that increased energy expenditure by 18% in obese mice while preserving lean muscle mass.

“Body weight responds to two levers: taking in fewer calories, or spending more energy,” said Anders Näär, professor of metabolic biology and nutrition at UC Berkeley and senior author of the study.

“GLP-1s work almost entirely on the first, so we went after the second.”

Researchers at the University of California, Berkeley, have identified an experimental compound that increased energy expenditure by up to 18% in obese mice while preserving lean muscle mass, according to findings published in Science Advances. The molecule, 5-tetradecyloxy-2-furoic acid (TOFA), also improved insulin sensitivity, lowered triglycerides, and reduced markers of fatty liver disease without requiring the animals to eat less or move more, ScienceDaily reported.

The study positions TOFA as a potential complement to GLP-1 medications such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), which primarily suppress appetite. When combined with those drugs in mice, TOFA produced greater improvements in body weight, blood glucose, insulin levels, and triglycerides than either treatment alone, the researchers found.

TOFA blocks fat production while activating fat-burning receptors

TOFA belongs to a class of compounds known as ACC inhibitors, which block enzymes involved in fatty acid synthesis. Unlike earlier ACC inhibitors that advanced to mid-stage clinical trials but raised blood triglycerides — a potential cardiovascular risk — TOFA did not increase triglyceride levels in the Berkeley experiments.

The researchers discovered that TOFA also activates two cellular receptors, PPARα and PPARδ, which regulate genes responsible for fat uptake and oxidation.

This dual action simultaneously slows lipid production and promotes the breakdown of existing fat for energy, a “coordinated metabolic response” that distinguished it from a two-compound approach tested in the same study, said Justin Y. Lee, the study’s first author and a postdoctoral researcher at UCSF who conducted the work as a Ph.D. student at Berkeley.

“TOFA appears to engage a coordinated metabolic response,” Lee said. “It is not simply blocking lipid synthesis. It is also activating energy expenditure pathways that may help the body handle excess lipid and glucose more effectively.”

Combination with GLP-1 drugs shows additive effects

In combination experiments, TOFA worked additively or synergistically with semaglutide and tirzepatide, Näär said. The researchers view the compound as complementary rather than a replacement for existing GLP-1 therapies, which can cause nausea and digestive side effects while increasing the risk of muscle loss during rapid weight loss.

Preserving lean mass is a recognized challenge with current obesity medications. Because GLP-1 drugs reduce food intake, patients can lose muscle along with fat, potentially contributing to frailty and metabolic complications over time. TOFA’s ability to drive fat loss without significant muscle reduction in mice addresses a distinct biological lever, the researchers said.

Human safety and efficacy remain unproven

All findings to date come from animal studies. The compound’s effectiveness and safety in humans have not been established, and the study description does not specify whether or when clinical trials might begin, ScienceDaily reported. TOFA was originally discovered in the 1970s, but its metabolic profile has only recently been characterized in this context.

To advance the research toward potential clinical applications, the Berkeley scientists have established a biotechnology company, ReRx Therapeutics.

Study details and funding

The research was funded through discretionary resources provided by UC Berkeley, with additional support from the UCSF Liver Center and the University of Michigan Animal Phenotyping Core. Additional authors include researchers from UC Berkeley, Massachusetts General Hospital, UC San Diego, Helmholtz Center Munich, and ReRx Therapeutics.

About the author: Health Desk

Health Desk at Archynewsy.